Key facts
- Peptomyc’s last known valuation is $40.5M (Dec 2020).
- It has raised $25.0M; the latest was Later Stage VC ($5.8M) in Mar 2026.
- Notable investors include European Innovation Council, INNVIERTE SICC, Asabys Partners, Caixa Emprendedor XXI, ACCIÓ — 20 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Peptomyc
- ·The full record, as it builds
Funding rounds
No funding rounds for Peptomyc are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Peptomyc
Developer of cell-penetrating mini-protein therapeutics designed to treat cancer. The company's therapeutics target the Myc oncogene, a central function in cancer cell survival, that lets cancer cells divide and survive treatment for the treatment of certain cancers of the lung and breast, as well as against brain tumors, enabling physicians and doctors to improve their chances of their patient's survival.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2014
- Employees
- 22
- Website
- peptomyc.com/
- Ownership
- Privately Held (backing)
Peptomyc doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Peptomyc shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Peptomyc in its N-PORT filings yet. We sweep new filings monthly.